durvalumab
Start here
The DeLLphi-305 study, published online in the New England Journal of Medicine on October 25, 2026, evaluates the efficacy and safety of tarlatamab combined with durvalumab as maintenance therapy for extensive-stage small-cell lung cancer. Tarlatamab is a bispecific T-cell engager, and durvalumab is a checkpoint immunotherapy; the combination tests whether an immune-directed maintenance strategy can improve outcomes in a disease where post-first-line options have historically been limited. The trial reports results on both efficacy and safety in this maintenance setting. Detailed clinician reaction, regulatory positioning, and how the regimen compares with existing maintenance approaches remain open questions as the field digests the full publication.
Written by a model from the reports · updated 1 day ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickDeLLphi-305 Phase III: Tarlatamab plus Durvalumab First-Line Maintenance in ES-SCLC Cuts Death Risk 58%
The Phase III DeLLphi-305 trial showed that tarlatamab combined with durvalumab as first-line maintenance therapy for ES-SCLC extended median overall survival from 12.7 months to 21.1 months, a 58% reduction in the risk of death (HR 0.42; 95% CI 0.32-0.54; P<0.001).
- nejm.orgPickTarlatamab–Durvalumab Maintenance for Extensive-Stage Small-Cell Lung Cancer
The NEJM published the DeLLphi-305 study online, evaluating the efficacy and safety of tarlatamab plus durvalumab as maintenance therapy for extensive-stage small-cell lung cancer.
Heat trend for this story
Heat now 15·Peak in the comparable set 22 (Oct 26 08:00)·Change over 24h in the comparable set -10%·Participants now 4
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.